Combining Gemcitabine, Endostar, and Envafolimab for Elderly Patients with Advanced Nasopharyngeal Cancer
Gemcitabine Combined With Endostar and Envafolimab in Elderly Patients With Locally Advanced Nasopharyngeal Carcinoma
This study is testing a new combination of three medications to see if it can help elderly patients with advanced nasopharyngeal cancer feel better and improve their health.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 65 Years and up |
| Sex | All |
| Sponsor | Zhejiang Cancer Hospital Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, Envafolimab |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT06055816 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the efficacy of a combination treatment involving Gemcitabine, Endostar, and Envafolimab specifically for elderly patients aged 65 and older who have been newly diagnosed with locally advanced nasopharyngeal carcinoma. The study aims to assess the safety and effectiveness of this treatment regimen in improving patient outcomes. Participants will be closely monitored for their response to the therapy and any potential side effects. The trial is designed to provide valuable insights into treatment options for this age group, which is often underrepresented in cancer research.
Who should consider this trial
Good fit: Ideal candidates for this study are elderly patients aged 65 years and older with newly confirmed locally advanced nasopharyngeal carcinoma and adequate organ function.
Not a fit: Patients with a history of cancer, prior treatments such as radiotherapy or chemotherapy, or a life expectancy of less than six months may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could offer a new therapeutic option for elderly patients suffering from advanced nasopharyngeal carcinoma.
How similar studies have performed: While the combination of these specific treatments in elderly patients with nasopharyngeal carcinoma is novel, similar approaches in other cancer types have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged ≥65 years with newly pathologically confirmed NPC * Karnofsky performance status ≥60 * Clinical stage III-IVA (Union for International Cancer Control and American Joint Committee on Cancer staging system for NPC, 8th edition) * Adequate organ function Exclusion Criteria: * Cancer history * Prior radiotherapy, cytotoxic chemotherapy, immunotherapy or target therapy * Life-expectance within 6 months
Where this trial is running
Hangzhou, Zhejiang
- Zhejiang Cancer Hospital — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Principal investigator: Xiaozhong Chen — Department of Radiation Oncology, Zhejiang Cancer Hospital
- Study coordinator: Xiaozhong Chen
- Email: chenxz@zjcc.org.cn
- Phone: 88128202
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.